Full-Time

Senior Scientist

Upstream Process Development

Stylus Medicine

Stylus Medicine

11-50 employees

In vivo genome editing for CAR-T

Compensation Overview

$155k - $170k/yr

Cambridge, MA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • PhD in Chemical/Biomedical Engineering, Biochemistry, Pharmaceutical Sciences, or related discipline with >4 years of experience, or BS/MS with >8 years of experience in biopharmaceutical or biotechnology development, including experience in developing scalable fermentation processes for producing plasmid DNA and/or recombinant products
  • In-depth experience and knowledge in fermentation process development, optimization, and process scale-up / scale-down model development
  • Familiarity with strain engineering and biocatalysis
  • Familiarity with performing operations in a cleanroom environment, applying controls to ensure aseptic processing
  • Demonstrated ability to coach and mentor junior researchers
  • Independently motivated and good problem-solving ability
  • Attention to detail and accuracy in developing, reviewing, and following protocols, SOPs, batch records and technology transfer documents
  • Demonstrated ability to work collaboratively across teams to meet project deliverables and timelines
  • Strong communication, decision-making and organizational skills
Responsibilities
  • Develop scalable production processes for nucleic acids and recombinant proteins
  • Leverage expertise in fermentation and mammalian cell culture to design, optimize, scale-up and characterize production processes
  • Independently utilize multivariate design of experiment approaches to improve productivity and optimize parameters for product quality
  • Drive fermentation platform development and new technology implementation to improve process performance, generation of predictive process models, and enhance process control and robustness
  • Design and implement in-process analytics to improve productivity while reducing process and product derived impurities
  • Maintain and troubleshoot equipment to ensure consistency and continuity of operations
  • Document, analyze and present experimental results internally and externally
  • Partner with CDMOs and provide technology transfer support to facilitate scale up
  • Interface with cross-functional teams to ensure programs are on track and stakeholders’ needs are met
  • Maintain accurate and reliable record keeping including database management, batch records, notebooks, and all other pertinent documentation
Desired Qualifications
  • Proficiency with statistical analysis software (e.g., JMP) is highly desired
  • Prior experience partnering with external CDMOs and conducting tech transfers preferred

Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.

Company Size

11-50

Company Stage

Series A

Total Funding

$85M

Headquarters

Cambridge, Massachusetts

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $85M in 2025 from RA Capital, Khosla, Lilly, and J&J.
  • Preclinical in vivo CAR-T data presented at ASGCT 2025.
  • Led by CEO Nuwaysir with 25+ years in cell therapy.

What critics are saying

  • Prime Medicine's PRIME Editing partners with BMS in January 2025.
  • Beam's base editing hits 40% efficiency in NHPs at ASGCT May 2025.
  • Arc licenses Hsu's IP exclusively to CRISPR Therapeutics February 2026.

What makes Stylus Medicine unique

  • Stylus combines engineered recombinases with LNP for in vivo genome integration.
  • Platform enables precise insertion of multi-kb payloads into T-cells directly.
  • Avoids ex vivo manufacturing complexities of traditional CAR-T therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Stylus Medicine who can refer or advise you

Benefits

Professional Development Budget

Company News

The Pharma Letter
May 14th, 2025
Stylus Medicine launches with $85M funding

Stylus Medicine, a biotech company based in Cambridge, USA, has emerged from stealth mode with $85 million in funding.

Yahoo Finance
May 14th, 2025
Stylus Medicine launches with $85m to advance in vivo gene editing

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline.

Fierce Biotech
May 13th, 2025
Stylus Medicine raises $85M for gene editing.

Stylus Medicine has emerged from stealth with $85 million in funding to develop next-gen in vivo genetic medicines. The financing includes a prior $40 million series A and a recent $45 million series A extension, with investors like RA Capital, Khosla Ventures, Eli Lilly, and J&J Innovation. Led by CEO Emile Nuwaysir, Stylus aims to simplify gene editing with a platform featuring recombinase technology. Preclinical data will be presented at the American Society of Gene & Cell Therapy meeting.

Endpoints News
May 12th, 2025
Stylus Medicine raises $85M for tech

Patrick Hsu's startup, Stylus Medicine, has launched with an ambitious goal to develop new gene insertion technologies beyond CRISPR. The company has successfully raised $85 million to support its development efforts.

Endpoints News
May 12th, 2025
Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

Stylus Medicine, an ambitious startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes...